HGH Fragment 176-191
Fragment 176-191 / HGH Frag / Frag 176-191
HGH Fragment 176-191 is a synthetic copy of the last 16 amino acids of human growth hormone, used for fat loss. Evidence comes from rodent and lab studies of this region, mostly of its close variant AOD-9604; no human trials of the fragment itself have been published. It is not FDA-approved.
Half-life
Not established in humans
Typical Dose
250–500 mcg/day
300/500Route
subcutaneous
Category
growth_hormone
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How HGH Fragment 176-191 is dosed in practice
Usually taken by subcutaneous (SubQ) injection. Typical range: 250–500 mcg/day. Half-life: Not established in humans. Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
Practitioner convention. Lab and rodent studies of the GH C-terminal region (mostly as AOD-9604) showed more fat breakdown without the insulin resistance of full GH; no human trial of Fragment 176-191 itself has been published, and AOD-9604's Phase 2b obesity trial did not support development.
- Practitioner protocols
- Laboratory and animal studies (1993–2001)
Popular in body recomposition communities. Users inject on empty stomach, wait 30+ minutes before eating. Best results reported when combined with fasted cardio. Effects subtle compared to full GH — works best as part of a comprehensive stack.
- Bodybuilding community fat-loss peptide protocols
- Community self-reports
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for HGH Fragment 176-191 and 90+ other compounds with Pro.
Upgrade to ProSafety & Contraindications
- Pregnancy or breastfeeding
- Known hypersensitivity to peptide compounds
- Active cancer (though lower risk than full GH)
HGH Fragment 176-191: common questions
What is HGH Fragment 176-191?
HGH Fragment 176-191 is a synthetic copy of the last 16 amino acids of human growth hormone, used for fat loss. Evidence comes from rodent and lab studies of this region, mostly of its close variant AOD-9604; no human trials of the fragment itself have been published. It is not FDA-approved.
How is HGH Fragment 176-191 dosed?
HGH Fragment 176-191 is usually taken by subcutaneous (SubQ) injection. Typical range in DoseCraft's library: 250–500 mcg/day. Expert (practitioner protocols): 250–500 mcg per day SubQ, split into 2 doses; Twice daily (AM fasted + pre-bed); 8–12 weeks. Experimental (early or animal data): 250 mcg twice daily (AM + PM); Twice daily, fasted; 8–12 weeks. These ranges describe what has been studied or used; they are not a prescription.
Is HGH Fragment 176-191 FDA-approved?
No. HGH Fragment 176-191 is not approved by the FDA for any use in people.
What is the half-life of HGH Fragment 176-191?
DoseCraft's library lists a half-life of Not established in humans. Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use HGH Fragment 176-191?
Listed contraindications: Pregnancy or breastfeeding; Known hypersensitivity to peptide compounds; Active cancer (though lower risk than full GH).
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.